4/10
10:19 am
hcat
Health Catalyst, Inc. (NASDAQ: HCAT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
Low
Report
Health Catalyst, Inc. (NASDAQ: HCAT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
4/10
10:13 am
hcat
Rating for HCAT
Low
Report
Rating for HCAT
4/10
08:06 am
hcat
Health Catalyst, Inc. (NASDAQ: HCAT) had its "sector weight" rating re-affirmed by analysts at KeyCorp.
Medium
Report
Health Catalyst, Inc. (NASDAQ: HCAT) had its "sector weight" rating re-affirmed by analysts at KeyCorp.
4/10
04:41 am
hcat
Rating for HCAT
Medium
Report
Rating for HCAT
4/10
04:41 am
hcat
Rating for HCAT
Medium
Report
Rating for HCAT
3/5
01:01 pm
hcat
Health Catalyst, Inc. (NASDAQ: HCAT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
Low
Report
Health Catalyst, Inc. (NASDAQ: HCAT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
3/5
12:35 pm
hcat
Rating for HCAT
Low
Report
Rating for HCAT
2/26
05:18 am
hcat
Rating for HCAT
Low
Report
Rating for HCAT
2/26
05:18 am
hcat
Rating for HCAT
Low
Report
Rating for HCAT
2/23
10:53 am
hcat
Rating for HCAT
Low
Report
Rating for HCAT
2/23
09:42 am
hcat
Rating for HCAT
Low
Report
Rating for HCAT
1/26
08:45 am
hcat
Health Catalyst, Inc. (NASDAQ: HCAT) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Low
Report
Health Catalyst, Inc. (NASDAQ: HCAT) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
1/26
08:45 am
hcat
Health Catalyst, Inc. (NASDAQ: HCAT) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Low
Report
Health Catalyst, Inc. (NASDAQ: HCAT) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
1/26
05:30 am
hcat
Rating for HCAT
Medium
Report
Rating for HCAT
1/26
05:30 am
hcat
Rating for HCAT
Medium
Report
Rating for HCAT